

Special Issue

Tuberculosis Vaccines and Host-Directed Therapies

Message from the Guest Editor

Tuberculosis is a major cause of morbidity and disease. Despite the existence of the Bacille Calmette Guerin (BCG) vaccine and drug regimens, the global epidemic of tuberculosis continues to grow. It is important to develop new and effective vaccines to end the epidemic. While the BCG vaccine effectively prevents childhood pulmonary tuberculosis, its efficacy in adults varies. As a result, the World Health Organization and TB researchers are working to develop better alternatives to reduce the risk of tuberculosis. In this Special Issue, we will discuss the latest developments in TB vaccine research, including advanced studies on the mechanism of the BCG vaccine, challenges in developing better vaccines, and potential new vaccines and promising host-directed therapies.

Guest Editor

Dr. Shibali Das

Department of Medicine, Division of Cardiology, Washington University in St. Louis, St. Louis, MO 63110, USA

Deadline for manuscript submissions

closed (30 November 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/196217

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).